Revance Therapeutics, Inc.
DelistedCIK 1479290fmd_0X1RRQ7H8N7F9GZE3D44E3HETDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2002 to Sep 30, 2024, 58 periods
Latest annual · FY2023
Millions- Total revenues
- 234
- Operating income
- (317)
- Net income
- (324)
- Free cash flow
- (223)
Latest quarter · Q3 FY2024
Millions- Total revenues
- 60
- Operating income
- (32)
- Net income
- (38)
- Free cash flow
- (41)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- +148.1%
- Revenue, 5 yearsFY2018 to FY2023
- +128.8%
- Net income, 5 yearsFY2018 to FY2023
- n/m
Revance Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $234 million | $132.6 million | +76.5% | 10-K 2024-02-28 · proof |
| Operating income | -$316.8 million | -$342 million | 10-K 2024-02-28 · proof | |
| Net income | -$324 million | -$356.4 million | 10-K 2024-02-28 · proof | |
| Cash from operating activities | -$216.6 million | -$193.5 million | 10-K 2024-02-28 · proof | |
| Free cash flow | -$223.5 million | -$196.8 million | 10-K 2024-02-28 · proof | |
| Total assets | $478.5 million | $581.9 million | -17.8% | 10-K 2024-02-28 · proof |
| Total liabilities | $630.1 million | $569.3 million | +10.7% | 10-K 2024-02-28 · proof |
| Cash and cash equivalents | $137.3 million | $109 million | +26% | 10-K 2024-02-28 · proof |
| Total debt | $429.1 million | $379.4 million | +13.1% | 10-K 2024-02-28 · proof |
- What was Revance Therapeutics, Inc.'s revenue in fiscal 2023?
- Revance Therapeutics, Inc. reported revenue of $234 million for fiscal 2023 (the year ended Dec 31, 2023), against $132.6 million the year before (+76.5%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Revance Therapeutics, Inc.'s operating income in fiscal 2023?
- Revance Therapeutics, Inc. reported operating income of -$316.8 million for fiscal 2023 (the year ended Dec 31, 2023), against -$342 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Revance Therapeutics, Inc.'s net income in fiscal 2023?
- Revance Therapeutics, Inc. reported net income of -$324 million for fiscal 2023 (the year ended Dec 31, 2023), against -$356.4 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Revance Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- Revance Therapeutics, Inc. reported cash from operating activities of -$216.6 million for fiscal 2023 (the year ended Dec 31, 2023), against -$193.5 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What was Revance Therapeutics, Inc.'s free cash flow in fiscal 2023?
- Revance Therapeutics, Inc. reported free cash flow of -$223.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$196.8 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What are Revance Therapeutics, Inc.'s total assets?
- As of Dec 31, 2023, Revance Therapeutics, Inc. reported total assets of $478.5 million, against $581.9 million a year earlier (-17.8%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What are Revance Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2023, Revance Therapeutics, Inc. reported total liabilities of $630.1 million, against $569.3 million a year earlier (+10.7%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What are Revance Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Revance Therapeutics, Inc. reported cash and cash equivalents of $137.3 million, against $109 million a year earlier (+26%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
- What is Revance Therapeutics, Inc.'s total debt?
- As of Dec 31, 2023, Revance Therapeutics, Inc. reported total debt of $429.1 million, against $379.4 million a year earlier (+13.1%). Source: the 10-K filed with the SEC on Feb 28, 2024. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1479290&period_type=annual&limit=5"Information only, not investment advice.